| Name | Title | Contact Details |
|---|
Semler Research Center Pvt. is a North Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.
Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. Its Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. The company’s platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. It has approximately 15 distinct immunotherapies in various stages of development, directly developed by the company and through strategic collaborations. The company’s products in clinical development stage comprise ADXS-HPV that is being evaluated in various clinical trials for cervical cancer, head and neck cancer, and anal cancer; ADXS-PSA for the treatment of prostate cancer; and ADXS-cHER2 for the treatment of overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company`s platform represents a potentially fundamental shift in what`s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.
Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More